- Home
- AEON vs NNVC Comparison
AEON vs NNVC Comparison
Compare AEON & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEON | NNVC |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | 8 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 21.2M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | AEON | NNVC |
|---|---|---|
| Price | $0.92 | $1.47 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.20 | N/A |
| AVG Volume (30 Days) | 122.6K | ★ 287.0K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.43 | $0.85 |
| 52 Week High | $1.45 | $2.23 |
Technical Indicators
Market Signals| Indicator | AEON | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 42.62 | 66.99 |
| Support Level | $0.91 | $1.35 |
| Resistance Level | $1.12 | $1.53 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 15.63 | 73.33 |
Price Performance
Historical ComparisonAbout AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.